Articles tagged: Actos

Byetta-Thyroid-CancerPancreatic cancer is one of the most deadly forms of cancer in the United States for multiple reasons. It is incredibly frightening to be told that you have pancreatic cancer, and many people feel like they have no options. If you or a loved one has been diagnosed with pancreatic cancer and you think it may have been caused by taking prescription diabetes medication you have options. Our law firm is currently accepting potential Byetta Pancreatic Cancer Lawsuits against the makers of the drug.

More on Byetta

Byetta is part of a class of drugs called GLP-1 receptor agonists, and it was approved by the Food and Drug Administration (FDA) back in April of 2005 for the treatment of type 2 diabetes in adults. Byetta is manufactured by Amylin Pharmaceuticals and until recently was marketed by both Amylin and Eli Lilly.

The Food and Drug Administration (FDA) approved Byetta in 2005 to assist adults with their type-2 diabetes and to help control blood sugar levels when other drugs weren’t enough. Byetta is typically taken through a twice-a-day injection to stimulate insulin production. In terms of the diabetes drug market, Byetta is a relatively new treatment method.

Byetta and Pancreatic Cancer

Multiple studies have proven that pancreatic cancer may in fact be a side effect of Byetta caused by pancreatitis. In the United States, it is estimated that pancreatic cancer is responsible for as many as 6% of all cancer deaths. In 2008, the Food and Drug Administration (FDA) had received over 30 reports of acute pancreatitis suffered by Byetta users since its introduction.

After receiving this information, the Food and Drug Administration (FDA) ordered Byetta’s manufacturer, Amylin, to conduct numerous studies related to the possibility and implication of Byetta causing acute pancreatitis. Further, the FDA required Byetta to look more deeply into the possibility that Byetta causes pancreatic cancer.

Also, the Food and Drug Administration (FDA) showed some worry that all drugs in the same class as Byetta may have similar potential of causing pancreatic cancer. Another such drug is Januvia that people worry may cause pancreatic cancer. Tests conducted on monkeys and rats have also shown an increased likelihood of developing Byetta thyroid cancer.

Diabetics are typically more likely to develop pancreatitis than the general population, but results from certain studies show that there may be an additional risk of pancreatic cancer among those diabetics who take Byetta to treat their diabetes.

Byetta Pancreatic Cancer Lawsuit

If you or a loved one has developed pancreatic cancer which you think may have been caused by taking prescription Byetta, you are not alone. Many people across the country are currently filing a Byetta Pancreatic Cancer Lawsuit against the manufacturers of the type-II diabetes drug. A Byetta Pancreatic Cancer Lawsuit claims that the manufacturer either already knew about the increased Byetta pancreatic cancer risks or should have known.

Please call a Byetta Pancreatic Cancer Lawyer today to discuss your options going forward with a potential Byetta Pancreatic Cancer lawsuit. All consultations are free of charge and lawsuits are pursued on a contingency-fee basis which means that you don’t pay anything unless your Byetta Pancreatic Cancer Lawsuit is successful.

Januvia Pancreatic Cancer

januviaRecent medical developments suggest that there may be a significant link between taking type 2 diabetes medication Januvia and an increased risk of suffering from pancreatitis or pancreatic cancer. Further investigation is ongoing to more fully understand a possible link between Januvia and pancreatic cancer.

Lead researcher at the Larry L HIllblom Islet Research Center at UCLA, Dr. Peter Butler stated that, “We have raised concern that there may be a link, but we haven’t confirmed it. We need to do more work to figure out whether this is real or not.”

Januvia functions by managing levels of blood sugar in the patient by inducing the production of glucagon-like peptide. Januvia is a new method of treating type 2 diabetes that claims to have advantages over more traditional diabetes medications. Because it is a new drug, however, researchers admit that they don’t understand Januvia as comprehensively as medications that have been on the market for longer.

When researchers compared Januvia to other medications used to treat type 2 diabetes, they discovered that it is as much as six times as likely to cause pancreatitis (inflammation of the pancreas) associated with patients who take Januvia. Further, researchers discovered an increase of more than 2.5 times as likely to develop pancreatic cancer among those who take Januvia.

Similar Januvia pancreas studies showed increases of pancreatitis and cancer among rats tested back in 2009 with Januvia. Researchers point out that a long-used drug for the treatment of type 2 diabetes, Metformin may actually reduce the risk of pancreatic cancer. Metformin has been around for much longer and is better understood by doctors.

Many doctors suggest prescribing alternative medications for patients who may have a higher risk profile for pancreatic cancer such as metformin, insulin or even Avandia and Actos. This is a difficult decision because Actos and Avandia have recently been associated with other forms of cancer and heart disease themselves. Specifically, the Food and Drug Administration has taken Avandia off the shelves at pharmacies and described a potential link between Actos and bladder cancer.

At this time, the manufacturers of Januvia are denying any proof that Januvia causes pancreatic cancer among patients. This denial of culpability or liability could prove to be important if further proof is unveiled. It is certainly frustrated for those patients who have developed pancreatic cancer after taking Januvia to see the manufacturers adamantly denying any responsibility.

Januvia Pancreatic Cancer Lawsuit

If you or a loved one has taken Januvia for the treatment of Type 2 diabetes and has subsequently developed pancreatic cancer, you are not alone. You may be entitled to financial compensation from the manufacturers through a Januvia Pancreatic Cancer Lawsuit against the makers of the potentially harmful drug. There is reason to believe that the manufacturer knew or should have known about these potential Januvia pancreatic cancer risks. Please call one of our pharmaceutical liability lawyers today for a free consultation regarding your Januvia Lawsuit. All Januvia lawsuits are processed on a contingency fee basis, which means that you don’t pay anything unless your case is successful.

Januvia and Pancreatic Cancer

januviaJanuvia (generic name sitagliptin) is a comparatively new entrant to the diabetes pharmaceutical market. Januvia is the first of a new class of diabetes drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors. Januvia is manufactured by large drug maker Merck, and is prescribed for the treatment of Type2 diabetes mellitus.

Unfortunately, many recent medical studies have pointed to a relation between DPP-4 medications like Januvia and significant complications. Patients who take diabetes drugs like Januvia may be at an increased risk of suffering from pancreatic cancer.

Januvia was originally manufactured by a subsidiary of Merck Pharmaceuticals and approved by the United States Food and Drug Administration (FDA) initially in late 2006. The release of Januvia marked the first of a new category of Diabetes drugs known as DPP-4 inhibitors. Januvia is a diabetes medication taken orally meant to help control blood sugar. People who suffer from diabetes commonly experience spikes in blood sugar, and Januvia is meant to temper those spikes.

While Januvia may be effective in the treatment of type 2 diabetes symptoms, it may also be responsible for severe and dangerous side effects. Recent reports have surfaced claiming that there may be a link between the use of Januvia and pancreatic cancer. United States regulators have allegedly received more than 80 claims of significant pancreatic disorders including Januvia pancreatic cancer.

Due to increased chatter of potential Januvia pancreatic cancer cases, a research team from the UCLA medical school decided to study the Food and Drug Administration (FDA) database of adverse Januvia events between 2004-2009. They determined that there may in fact be an increased risk of Januvia pancreatic cancer when taking the type 2 diabetes drug.

The report claims that drugs like Januvia may increase the risk of cancer due to the impact that they have on the immune system. The American Gastroenterological Association’s (AGA) official newspaper, GI & Hepatology News published a report claiming that the risk of pancreatic cancer was elevated by Januvia by 6.7 times compared to related control medications.

Pancreatic cancer, or carcinoma of the pancreas describes the condition of cancerous cells infiltrating the pancreas. The pancreas is the organ found near the stomach which exudes enzymes to the intestines designed to assist the organ in the absorption of nutrients. Unfortunately, pancreatic cancer, including Januvia pancreatic cancer is particularly insidious because it is rarely diagnosed early on and it tends to spread rapidly through the body.

Januvia and Pancreatic Cancer Lawsuit

If you or a loved one has taken Januvia for the treatment of Type 2 diabetes and has subsequently developed pancreatic cancer, you are not alone. You may be entitled to financial compensation from the manufacturers through a Januvia Pancreatic Cancer Lawsuit  against the makers of the potentially harmful drug. There is reason to believe that the manufacturer knew or should have known about these potential Januvia pancreatic cancer risks. Please call one of our pharmaceutical liability lawyers today for a free consultation regarding your Januvia Lawsuit. All Januvia lawsuits are processed on a contingency fee basis, which means that you don’t pay anything unless your case is successful.

Actos Risk of Heart Failures

A recent report about the high cardiovascular risk associated with the diabetes drug Avandia has caused a steep decline in its sales and resulted in a large increase in the sales of competing diabetes drug Actos. Actos has been so successful lately because it has been perceived as the ‘safer’ of the two options. Both Actos and Avandia are part of the family of drugs known as thiazolidinediones which are used to decrease insulin resistance of body tissues and alter the body’s production of cholesterol.

The study which plagued Avandia originally stated that they didn’t see the same heart failure risks associated with Actos, but new information has come to light regarding Actos and heart failure. A new study published examined the records of over 28,000 patients who took both drugs and determined that there may in fact be a higher risk of heart failure with the use of Actos. Some of the results of the study are as follows:

  • 96 patients on Avandia suffered a heart attack, compared with 121 on Actos;
  • 265 on Avandia suffered heart failure, compared with 243 on Actos;
  • 24 on Avandia suffered both heart attack and heart failure, compared with 18 on Actos;
  • 217 on Avandia and 217 on Actos died.

They reported in the journal Circulation: Cardiovascular Quality and Outcomes that, when they accounted for potential confounding effects, including age, gender and prior heart disease, about 4% of each group had a heart attack, heart failure or died. Specifically: “What distinguishes this latest study from other claims-based analyses is its analysis of death records, which include out-of-hospital deaths,” Wertz said in a statement. The study also followed patients for a longer period of time than earlier studies and the patients were younger, she added. Unlike the earlier studies, however, it did not include strokes in the data, which may account for part of the difference in outcomes.

This study about Actos’ risk of heart failure caused the diabetes drug to also be required to carry a ‘black box’ warning about heart failure. A black box warning is the strongest provision that the FDA enacts short of removing a drug from the market. Recent studies have also been published warning of an increased risk of bladder cancer associated with the use of Actos.

Actos Heart Failure Lawsuit

If you or a family member took Takeda Pharmaceutical’s drug Actos (pioglitazone) and you have developed heart failure, we encourage you to contact a pharmaceutical lawyer at our firm immediately. An experienced pharmaceutical products liability lawyer at the Willis Law Firm can assist you in legal action in a potential Actos heart failure lawsuit against the makers of the drug.

Please fill out our online legal evaluation form to the right or call us and we will contact you within 4-12 hours for a free confidential case review. Contact our law firm immediately so that we may explain the rights and options available to you and your family.

According to a clinical study in France, there is an increased risk of bladder cancer associated with Takeda’s drug Actos (pioglitazone). Surveying 1.5 million diabetic patients, this study also found that the risk of bladder cancer sharply increased with usage of over 12 months as well as with increased dosage. Prior to the study conducted in France, bladder cancer was similarly observed in male rats receiving clinical equivalent doses of (Actos) pioglitazone.

As a consequence of these findings, Takeda’s Actos will be completely removed from the pharmaceutical market in France. Similarly, the German Federal Institute for Drugs and Medical Devices has already advised doctors to cease in prescribing Actos to their diabetic patients. While Actos is still currently available in the United States, the FDA has been conducting rigorous safety reviews of the drug and further exploring its alarming and devastating link to bladder cancer.

Additionally, the United States FDA has reacted to the findings of the Actos Study in France by amending the warnings and precautions section of all Actos drug labels to reflect it’s dangerous and previously unreported correlation to bladder cancer. As of 8-4-2011, the FDA announced that their approval of the inclusion that the use of pioglitazone for more than one year may be associated with an increased risk of bladder cancer. Because Takeda first introduced Actos into the market in the 1990’s, this means that many diabetes patients have been using this drug for decades without knowledge of its devastating risk of leading to bladder cancer.

In response to the French data, the FDA declared that healthcare professionals should not prescribe Actos (pioglitazone) to patients with active bladder cancer. In addition, Actos should be used with caution in patients with a prior history of bladder cancer because the benefits of blood sugar control must be carefully weighed against the risks for bladder cancer recurrence.

The hugely popular Actos has ranked among the top ten selling prescription medicines in the United States. In 2010 Actos had sales of over $3.4 billion, and accounted for 27% of Takeda Pharmaceuticals revenue. However, after the alarming results of the recent study in France, the usage of Actos for Diabetes must be carefully weighed against its link to bladder cancer. In the words of Dr. Harlan Krumholz, a Yale School of Medicine professor, “The consensus already is that (Actos) should only be considered … after patients have exhausted all other options.”

Actos Bladder Cancer Lawsuit

If you or one of your family members took Takeda Pharmaceutical’s drug Actos (pioglitazone) and have developed bladder cancer, we encourage you to contact a pharmaceutical lawyer at our firm immediately. An experienced pharmaceutical products liability lawyer at our law firm can inform and assist you regarding legal action in a potential Actos bladder cancer lawsuit against the makers of the drug.

Please fill out our online legal evaluation form to the right or call 1-800-883-9858 and we will contact you within 4-12 hours for a free confidential case review. Contact our law firm immediately so that we may explain the rights and options available to you and your family.

Bladder Cancer from Actos

Only a week after officials in both France and Germany began restricting the prescriptions of the diabetes drug Actos made by Takeda Pharmaceuticals, the US Food and Drug Administration (FDA) will now require additional warnings that the use of Actos for more than a year might be linked with an increased risk of developing bladder cancer. Only a week prior, a French study with similar findings propelled French officials to suspend the use of Actos and officials in Germany have recommended that doctors not prescribe Actos to new patients.

The statement by the FDA is in response to a 5-year interim analysis of an ongoing 10-year study of Actos risk of bladder cancer. The FDA’s analysis claims that while they don’t see any overall increase risk of bladder cancer with the use of Actos, they noted an increased Actos bladder cancer risk among patients taking Actos for more than a year as well as those taking higher dosages of Actos. French and German studies, however, did claim that there is an overall increased risk of bladder cancer with Actos as well as an even higher risk the longer Actos is taken.

The French decision was made by its version of the FDA, the AFSSAPS which based their move on a study conducted by a national French insurer which examined results of more than 1.5 million individuals between the ages 40 and 79 years old being treated with Actos between 2006 and 2009. France’s move on Actos has triggered a study by the European Medicines agency, the umbrella drug regulatory agency of Europe. Their study is currently ongoing. A further report in an issue of Diabetes Care, reported 93 incidences of bladder cancer among Actos patients in the FDA Adverse Event Reporting system databases spanning between 2004 and 2009.

Between January 2010 and October 2010 more than 2.3 million patients filled a prescription for diabetes drug Actos. Actos has enjoyed great results following the restrictions placed on sister drug Avandia. Actos has been perceived as the ‘safer’ of the two diabetes drug, but new results linking Actos to bladder cancer might change that perception. In addition to being linked with bladder cancer, Actos has also been recently linked to increased heart failure and bone fractures.

Actos Bladder Cancer Lawsuit

If you or a family member took Takeda Pharmaceutical’s drug Actos (pioglitazone) and you have developed bladder cancer, we encourage you to contact a pharmaceutical lawyer at our firm immediately. An experienced pharmaceutical products liability lawyer at the Willis Law Firm can assist you in legal action in a potential Actos bladder cancer lawsuit against the makers of the drug.

Please fill out our online legal evaluation form to the right or call us and we will contact you within 4-12 hours for a free confidential case review. Contact our law firm immediately so that we may explain the rights and options available to you and your family.

The United States Food and Drug Administration (FDA) came out with a statement Wednesday, June 15 2011 warning that the diabetes medication Actos (generic: pioglitazone) increases the risk of bladder cancer by no less than 40% if Actos is used for longer than a year, or with higher dosages of Actos. There have been suspicions for some time now that Actos causes bladder cancer, but the FDA’s recent release makes the claims suggesting a correlation between diabetes drug Actos and cancer even stronger.

Going forward, the Food and Drug Administration (FDA) is requiring modifications to Actos’ drug label in order to portray the recent findings that Actos may significantly increase the risk of bladder cancer. Actos is manufactured by drug-maker Takeda Pharmaceutical North America. This release by the FDA is a major blow to the class of diabetes medications known as thiazolidinediones, which Actos is a part of. Avandia, another diabetes medication in the same class, has also been under fire lately due to reports that Avandia causes increased risk of cardiovascular disease.

As of now, the US FDA is not taking any further action against Actos other than mandatory label changes until further test results return. Actos has already been suspended in France, and officials in Germany have warned physicians not to prescribe Actos to new patients. The Food and Drug Administration (FDA) announced back in September 2010 that Actos was under investigation, and these warnings are a result of those tests.

The data which suggests an increased risk of bladder cancer with Actos comes from an ongoing 10-year study of over 190,000 diabetes patients. The increased risk of bladder cancer specifically comes to those who have taken Actos for more than a year or who have taken larger dosages. A French study showed a 22% increase in risk of bladder cancer to those who had ever taken Actos at all. The French study revealed a 75% increased risk of bladder cancer for those who had taken a cumulative dosage of over 28,000 milligrams of Actos.

Actos Bladder Cancer Lawsuit

If you or a family member took Takeda Pharmaceutical’s drug Actos (pioglitazone) and you have developed bladder cancer, we encourage you to contact a pharmaceutical lawyer at our firm immediately. An experienced pharmaceutical products liability lawyer at the Willis Law Firm can assist you in legal action in a potential Actos bladder cancer lawsuit against the makers of the drug.

Please fill out our online legal evaluation form to the right or call 1-800-883-9858 and we will contact you within 4-12 hours for a free confidential case review. Contact our law firm immediately so that we may explain the rights and options available to you and your family.

The FDA released a safety announcement on June 15, 2011 informing the public that the use of Takeda Pharmaceutical’s medication Actos (pioglitazone) for diabetes for over a year may be associated with an increased risk of Bladder Cancer from Actos. Takeda’s Actos will now be required to add information about this increased risk of bladder cancer to the label of the diabetes medication.

The FDA announcement is a result of a five-year study which showed an increased risk of bladder cancer with the use of Actos over a long period of time. This came to the attention of the FDA after a similar study conducted in France, Actos Bladder Cancer Study in France, suggested an increased risk of bladder cancer with the use of the drug Actos (pioglitazone). The FDA plans to continue its study of Actos (pioglitazone) to further evaluate the increased risk of bladder cancer. Between January 2010 and October 2010 over 2.3 million patients filled prescriptions for pioglitazone-containing products including the diabetes medication Actos.

What is Actos?

Actos is a drug made by the pharmaceutical company Takeda to treat type-2 diabetes. In 2008 Takeda’s Actos (pioglitazone) was the 10th highest selling drug in the United States, with sales over $2.4 billion. Actos is in the same class of drugs as Avandia (rosiglitazone), which has had a correlation with increased risk of heart problems. Due to the increased concerns about Avandia, sales of the drug Actos have increased greatly in recent years.

Symptoms of Actos Bladder Cancer

Recent studies performed by the FDA and French officials have suggested that there may be an increased risk of bladder cancer with the use of Actos (pioglitazone). Some possible symptoms of bladder cancer caused by Actos may include some or all of the following:

  • Blood found in the urine
  • Pain while urinating
  • Frequent urination
  • Sensation of needing to urinate without results

Actos Tv Ad

Many of our clients have seen our nationwide Actos lawsuit television commercial discussing the dangers of Actos and bladder cancer. What the Actos TV commercial and Actos ads don’t discuss is the increased risks to some Actos users of having heart attacks and strokes. For more information, please read: Actos Risk of Heart Failures. If you or a loved one have taken Actos and developed bladder cancer or had a heart attack while taking Actos, then contact our law firm to discuss your legal options. Additional information: Diabetes Drug Actos and Bladder Cancer Lawsuits.

Actos Bladder Cancer Lawsuit

If you or a family member took Takeda Pharmaceutical’s drug Actos (pioglitazone) and you have developed bladder cancer, we encourage you to contact a pharmaceutical lawyer at our firm immediately. An experienced pharmaceutical products liability lawyer at the Willis Law Firm can assist you in legal action in a potential Actos bladder cancer lawsuit against the makers of the drug.

Please fill out our online legal evaluation form to the right or call 1-800-883-9858 and we will contact you within 4-12 hours for a free confidential case review. Contact our law firm immediately so that we may explain the rights and options available to you and your family.